Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

Contact Supplier

Jai Radhe Sales is your partner for all your sourcing needs.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 USDMF

1 API Suppliers
1 USDMF

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 111358-88-4, Cep-701, Kt-5555, Spm-924, Kt5555, Cep 701

Molecular Formula

C₂₆H₂₁N₃O₄

Molecular Weight

439.5 g/mol

InChI Key

UIARLYUEJFELEN-LROUJFHJSA-N

FDA UNII

DO989GC5D1

Lestaurtinib is an orally bioavailable indolocarbazole derivative with antineoplastic properties. Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3. (NCI05)

1 2D Structure

Lestaurtinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one

2.1.2 InChI

InChI=1S/C26H21N3O4/c1-25-26(32,12-30)10-18(33-25)28-16-8-4-2-6-13(16)20-21-15(11-27-24(21)31)19-14-7-3-5-9-17(14)29(25)23(19)22(20)28/h2-9,18,30,32H,10-12H2,1H3,(H,27,31)/t18-,25+,26+/m1/s1

2.1.3 InChI Key

UIARLYUEJFELEN-LROUJFHJSA-N

2.1.4 Canonical SMILES

CC12C(CC(O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O

2.1.5 Isomeric SMILES

C[C@@]12[C@](C[C@@H](O1)N3C4=CC=CC=C4C5=C6C(=C7C8=CC=CC=C8N2C7=C53)CNC6=O)(CO)O

2.2 Other Identifiers

2.2.1 UNII

DO989GC5D1

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Cep 701

2. Cep-701

3. Cep701

4. Kt-555

5. Kt-5555

6. Kt5555

7. Sp-924

8. Sp924

9. Spm-924

2.3.2 Depositor-Supplied Synonyms

1. 111358-88-4

2. Cep-701

3. Kt-5555

4. Spm-924

5. Kt5555

6. Cep 701

7. Sp924

8. Sp 924

9. Sp-924

10. Kt 5555

11. Kt-555

12. Cep701

13. C26h21n3o4

14. Chembl603469

15. Do989gc5d1

16. A-154475.0

17. (9s,10s,12r)-2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epoxy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one

18. Ncgc00168772-01

19. (5s,6s,8r)-6-hydroxy-6-(hydroxymethyl)-5-methyl-7,8,14,15-tetrahydro-5h-16-oxa-4b,8a,14-triaza-5,8-methanodibenzo[b,h]cycloocta[jkl]cyclopenta[e]-as-indacen-13(6h)-one

20. A-154475

21. Lestaurtinib [usan]

22. Lestaurtinib (usan/inn)

23. Lestaurtinib [usan:inn]

24. Unii-do989gc5d1

25. 4otg

26. A 1544750

27. Cep-701 Hydrate

28. Lestaurtinib; Cep701

29. Lestaurtinib [inn]

30. Dsstox_cid_26778

31. Dsstox_rid_81897

32. Dsstox_gsid_46778

33. Lestaurtinib [mart.]

34. Lestaurtinib [who-dd]

35. A 154475.0

36. Gtpl5672

37. Schembl1649693

38. Dtxsid5046778

39. Chebi:91471

40. 9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9s,10s,12r)-

41. 9,12-epoxy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1,6]benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9s,10s,12r)-

42. Bcp06977

43. Zinc3781738

44. Tox21_112633

45. Bdbm50308060

46. Mfcd09840836

47. Nsc772196

48. Nsc800782

49. Akos024457603

50. Ac-5243

51. Am81228

52. Db06469

53. Nsc-772196

54. Nsc-800782

55. Ncgc00168772-02

56. Ncgc00168772-03

57. Ncgc00168772-04

58. Hy-50867

59. Cas-111358-88-4

60. Cs-0004336

61. D04696

62. J-002567

63. Q6531771

64. Brd-k23192422-001-01-1

65. (15s,16s,18r)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8,10,12,20,22,24-nonaen-3-one

66. (15s,16s,18r)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8(13),9,11,20(25),21,23,26-nonaen-3-one

67. (15s,16s,18r)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one

68. (9s,10s,12r)-10-hydroxy-10-(hydroxymethyl)-9-methyl-2,3,9,10,11,12-hexahydro-9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one

69. (9s,10s,12r)-2,3,9,10,11,12-hexahyd Ro-10-hydroxy-10-(hydroxymethyl)-9-methyl-9,12-epo Xy-1h-diindolo[1,2,3-fg:3',2',1'-kl]pyrrolo[3,4-i][1, 6]benzodiazocin-1-one

70. 16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.1^{15,18}.0^{2,6}.0^{7,27}.0^{8,13}.0^{19,26}.0^{20,25}]octacosa-1(26),2(6),7(27),8(13),9,11,20(25),21,23-nonaen-3-one

71. 9,12-epoxy-1h-diindolo(1,2,3-fg:3',2',1'-kl)pyrrolo(3,4-i)(1,6)benzodiazocin-1-one, 2,3,9,10,11,12-hexahydro-10-hydroxy-10-(hydroxymethyl)-9-methyl-, (9s-(9alpha,10beta,12alpha))-

2.4 Create Date

2005-08-08

3 Chemical and Physical Properties

Molecular Formula	C₂₆H₂₁N₃O₄
Molecular Weight	439.5 g/mol
XLogP3	2.2
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	1
Exact Mass	439.15320616 g/mol
Monoisotopic Mass	439.15320616 g/mol
Topological Polar Surface Area	88.6 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	886
Isotope Atom Count	0
Defined Atom Stereocenter Count	3
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Investigated for use/treatment in pancreatic cancer, prostate cancer, and leukemia (myeloid).

5 Pharmacology and Biochemistry

5.1 Mechanism of Action

Lestaurtinib inhibits autophosphorylation of FMS-like tyrosine kinase 3 (FLT3), resulting in inhibition of FLT3 activity and induction of apoptosis in tumor cells that overexpress FLT3.

API SUPPLIERS